

USSN: 10/075,715
Attorney Docket No: 1059.00073

IN THE CLAIMS:

1. (Currently amended) A method of promoting neurogenesis comprising the step of:
~~administering a therapeutic amount of a nitric oxide-donor therapeutic compound for increasing levels of cGMP to a patient in need of neurogenesis promotion post stroke.~~
2. (Currently Amended) A compound for promoting neurogenesis comprising an effective amount of a ~~nitric oxide-donor therapeutic compound that increases levels of cGMP, sufficient to promote neurogenesis.~~
3. (Currently amended) A neurogenesis promoter comprising a ~~nitric oxide-donor in a pharmaceutically acceptable carrier therapeutic compound that increases levels of cGMP, said therapeutic compound capable of promoting neurogenesis in a pharmaceutically acceptable carrier.~~
4. (Currently Amended) The neurogenesis promoter according to claim 3, wherein said ~~nitric oxide-donor therapeutic compound~~ augments nitric oxide in a tissue.
5. (Previously Presented) The neurogenesis promoter according to claim 4, wherein said nitric oxide donor is selected from the group consisting essentially of phosphodiesterase inhibitors, L-arginine, sildenafil, and atorvastatin.
6. (Currently Amended) A method of augmenting the production of neurons by administering an effective amount of a ~~therapeutic compound that increases levels of cGMP, nitric oxide donor to a site in need of augmentation.~~
7. (Currently amended) A method of increasing neurological function by administering an effective amount of a ~~nitric oxide-donor to a patient therapeutic~~

USSN: 10/075,715
Attorney Docket No: 1059,00073

compound that increases levels of cGMP nitric-oxide-donor to a patient in need of increased neurological function after neurological damage has occurred.

8. (Currently amended) A method of increasing cognitive and neurological function by administering an effective amount of a therapeutic nitric-oxide-donor compound that increases levels of cGMP to a patient in need of increased cognitive and neurological function after neurological and cognitive damage has occurred.

9. (New) A method of promoting neurogenesis comprising the step of increasing levels of cGMP in a patient in need of neurogenesis promotion.

10. (New) A method of augmenting the production of neurons by increasing cGMP levels at a site in need of augmentation.

11. (New) A method of increasing neurological function by increasing levels of cGMP in a patient in need of increased neurological function.

12. (New) A method of increasing cognitive and neurological function by increasing levels of cGMP in a patient in need of increased cognitive and neurological function.

13. (New) A compound for increasing *in vivo* levels cGMP for use in generating neurons.